US needs to look differently at public health preparedness, says former FDA commissioner Gottlieb
Speaking at CPHI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities
The ongoing coronavirus pandemic means the US will need to look at public health preparedness through the lens of national security and treat it on par with other kinds of national security threats, according to former US Food and Drug Administration Commissioner, Dr Scott Gottlieb on Tuesday.
Speaking at the hybrid CPHI North America event, Gottlieb said the pandemic had changed the course of history, reset the global order in many significant ways from a geopolitical standpoint, cost trillions of dollars and superseded all other national priorities for more than a year.
“We’re seeing the outsized impact that pathogens and pandemics can have and it means we have to reset how we look at these kinds of risks,” he told delegates.
Outlining the practical measures to tackle future healthcare crises, Gottlieb said the US needs to build different capacities.
“We clearly didn’t have the capacities we thought we had and that we certainty needed,” he said.
He said that the after US’ pandemic planning in 2003, which was focused on concern around H5N1 flu, the country invested in building out certain capacities such as cell-based manufacturing facilities for vaccines, as well as stockpiles and antivirals.
“What happened over time was those efforts atrophied and we didn’t continue to invest in keeping them ready,” he said. “We had this idea that we would create a warm base of preparedness when really what we needed was a hot base of preparedness. You can’t build a vaccine manufacturing plant and mothball it. You really need to be operating these things at scale; in part, because you need to be able to make continuing investments to keep facilities up to date and in part because the only way you can retain personnel to run these kinds of facilities and be ready to scale them up in the event of an emergency is to be operating them.”
He described the country’s prior focus on flu as a mistake: “Even after SARS and MERS came along and it was apparent that coronaviruses were on the march and represented a different kind of threat, we never pivoted our thinking; we never invested in broader capacities that looked beyond flu.”
To register for our four-week hybrid event, CPHI North America and to watch the full webinar on demand, click here.
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance